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Patienthood and participation in the digital era
Sonja Erikainen , Martyn Pickersgill, Sarah Cunningham-Burley and
Sarah Chan
Abstract
The ‘digital era’ of informatics and knowledge integration has changed the roles and experiences of patients, research
participants and health consumers. No longer figured (merely) as passive recipients of healthcare services or as benefi-
ciaries of top-down biomedical information, individuals are increasingly seen as active contributors in healthcare and
research. They are positioned into multiple roles that are experienced simultaneously by those who access and co-produce
digital content that can easily be transformed into data. This is contextualised by ‘big data’ technologies that have altered
biomedicine, enabling collation and analysis of myriad data from digitised records to personal mobile data. Social media
facilitate new formations of communities and knowledge enacted online, while novel kinds of commercial value emerge
from digital networks that enable health data commodification. In this paper, we draw from exemplary digital era shifts
towards participatory medicine to cast light on the rapprochements between patienthood, participation and consumption,
and we explore how these rapprochements are mediated by, and materialise through, the use of participatory digital
technologies and big data. We argue that there is a need to use new conceptual tools that account for the multiple
roles and experiences of patient–participant–consumers that co-emerge through digital technologies. We must also
ethically re-assess the rights and responsibilities of individuals in the digital era, and the implications of digital era
changes for the future of biomedicine and healthcare.
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In recent years, scholars across disciplines1–7 have
documented shifts in the nature of patienthood and
participation. These have been propelled by wider
socio-technological transformations that have changed
biomedical research, healthcare and social interaction
in the so-called ‘digital era’ of data analytics, informat-
ics and social media in societies with well-established
digital networks. Changes cluster around the inter-
twined phenomena of ‘big data’ and the increased
‘datafication’ of once-unquantified aspects of life,3,8
and the modes of interconnectivity, communication,
and information access, sharing and co-production
that are enabled by digital platforms. In this context,
individuals are continuously and simultaneously
positioned as both patients and ‘active’ participants
in biomedicine and healthcare by healthcare providers,
researchers and research organisations, and policy-
makers – as well as by themselves and each other.
Increasingly, citizens are figured not (just) as passive
recipients of healthcare services by healthcare profes-
sionals or as mere beneficiaries of top-down biomedical
information and health research by researchers, but as
active, engaged members in healthcare and biomedical
research production. This is exemplified by increasing
trends towards what has been called ‘participatory’
medicine and healthcare,9 including trends towards
personalised medicine and genomics in particular.
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These aim to provide individuals with personalised bio-
medical and health information that are both
co-produced by and enable individuals to act on and
take responsibility for their own health. In the context
of increasing commercialisation and globalisation of
medical and healthcare services, many people also
occupy the role of health consumers in ways that are
facilitated by digital health markets and direct-
to-consumer (DTC) medicine.10 The extent to which
these trends are bringing new forms of participation
and empowerment at the level of the individual and
collectives is, of course, contested. The ways in which
patienthood and participation in healthcare and health
relevant data production are becoming intertwined and
reconfigured demand critical interrogation.
Existing analyses and commentaries have highlight-
ed many potentially empowering as well as dangerous
aspects of, and prospects that accompany, the ‘activa-
tion’ and ‘responsibilisation’ of patients and citizens in
relation to health and medical information in the dig-
ital era.5,6,11 In this paper, drawing on such scholarship
and with examples from our own work, we aim to pro-
vide a synoptic account that synthesises the relevant
conceptual issues around three key areas: biomedicine
and big data; datafication and the construction of com-
munity; and commercialising and consuming health.
In this way we map how participatory biomedicine
and healthcare in the context of social and digital
media are blurring and merging the roles and experi-
ences of patients, (research) participants and health
consumers. In particular, we examine the seemingly
disparate but concurrent move towards population
level and ‘personalised’ biomedicine; the processes
and practices of (self-)datafication and online health
community formation; and the commodification of
user-generated content and DTC medicine.
Our aim is not to provide a comprehensive overview
of all the diverse emerging digital era formations of
patienthood and participation, but rather to draw
from exemplary shifts towards participatory medicine
to focus on the rapprochements between patienthood,
participation and consumption. We explore how these
rapprochements are simultaneously mediated by, and
materialise through, the use of participatory digital
tools and big data biotechnologies, which are reconfi-
guring the roles of patients, participants and consumers
– roles that are often experienced simultaneously by
those who access, share and co-produce digital content.
Patient–participant–consumers are both subjects and
agents of biomedical practices, bringing to the fore
that we must not only account for the multiple
roles and experiences that co-emerge through digital
technologies, but also ethically re-assess the rights
and responsibilities of individuals in the digital era.
Such interdisciplinary theoretical, methodological
and normative tools are required to analyse and appro-
priately respond to the effects of intersecting and merg-
ing digital and biomedical shifts upon citizens as well as
healthcare systems and institutions across different
contexts. While myriad aspects of these shifts have
been explored by others, these analyses have often
remained separate, and the intersections of different
digital era changes have achieved less attention and
scrutiny. The next section provides some wider context
before the paper focusses on three key areas of possible
transformation.
Contextualising digital era patienthood and
participation
The ‘digital era’ is characterised not only by unprece-
dented levels of interconnectivity, information access,
circulation and co-production, but also by increasing
speed, spread and dynamism in relation to knowledge
and information turnover. This has been argued to
make the information flows of the digital ‘information
society’ challenging to manage and control.12,13
The current scope of digitally mediated forms of infor-
mation provision and knowledge management cut
across most cultural, social and economic spheres of
life.14 Indeed, the impact of, and challenges posed by,
digital era changes have been analysed in relation to
myriad domains ranging from governance and public
sector organisation15 to human resource management16
to marketing17 to cultural phenomena like ‘fandom’18
in addition to health.1–7 The emergence of interactive
Web 0.2. digital and social media technologies
that enable users to (co-)produce and circulate digital
content have facilitated increasing practices of, and
platforms for, ‘prosumption’, which refers to the ability
of users to both produce and consume information
online.19 Prosumption has been further enabled by
mobile devices and wearable sensors that can simulta-
neously produce, collate and facilitate access to myriad
forms of digital data. The potential and impact of these
technologies across sectors and domains have been
heralded by technology companies, policy makers and
cultural commentators as a ‘digital revolution’.
In the context of biomedicine and healthcare, digital
health technologies and applications have been argued
to carry revolutionary potential to transform medicine
and healthcare in the near future in ways that are
promoted as empowering expressions of participatory
medicine and ‘citizen science’. Hood et al.20, for exam-
ple, have envisioned that in the next few years, ‘each
patient will be associated with a virtual data cloud of
billions of data points’ and that these data will be
‘multi-scale’ as well as ‘extremely heterogeneous in
type’. They argue that this digitisation or ‘datafication’
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of patients will, in turn, facilitate a new model of
healthcare that is simultaneously predictive, preventa-
tive, personalised and participatory. It will enable
patients to benefit from personalised medical informa-
tion derived from population data stratification, and to
take responsibility for managing and improving their
own health by monitoring their health data.
In contrast to these promissory visions, others have
argued that aspiring towards such ‘predictive, preventa-
tive, personalised and participatory’ medicine represents
ethically questionable demands for idealistically indepen-
dent individuality,21 medical (self-)surveillance and
health-related ‘responsibilisation’, whereby the responsi-
bility for healthcare is increasingly transferred from
public and national healthcare services to individuals.11
Emphasis on, and celebration of, ‘individual responsibil-
ity’ has been argued to reflect neoliberal discourses
around decreasing state accountability,1 and to mirror
Foucauldian modes of power and discipline whereby
individuals learn to actively discipline themselves against
established norms of health.22 While framed as patients’
and citizens’ empowerment, the promotion and use of
‘participatory’ digital health tools and medical self-
monitoring technologies can thus be seen as a medicalised
form of ‘responsibilisation’.
Simultaneously, the potentials of digital technolo-
gies in general and digital health technologies in par-
ticular are constrained by inequalities of access
and benefit distribution that derive from broader
inter- and intra-national socio-economic disparities.
A global ‘digital divide’ has materialised along socio-
economic lines in multidimensional ways that are char-
acterised by disparities of access to, and use of, digital
tools both between high-income and low- and middle-
income countries, and between the rich and poor in
each country,23 as well as along the lines of social divid-
ers such as generational and gendered relations.24
In the context of medicine and healthcare, the ‘digital
divide’ is intertwined with well-known global health
disparities around access to, and quality of, healthcare,
which means that inter- and intra-nationally disadvan-
taged and socio-economically marginalised populations
also carry a disproportionate burden of disease.25
The ‘digital era’ and its implications for medicine and
healthcare have thus not materialised everywhere, and
for everyone, to the same degree, which both constrains
its healthcare as well as more general potential, and
implies that the analysis we advance in this paper is,
from the outset, delimited by the scope and reach of
digital influence.
Changes in the roles and experiences of ‘patient-
hood’ and ‘participation’ in the ‘digital era’ are thus
intertwined with, and are taking shape in the context
of, broader social-economic and geo-political divisions
and shifts beyond biomedicine, which in turn are
shaping the current bio-technological and healthcare
landscape. Our analysis must be located within this
wider context, but it also aims to move beyond both
the established promises and fears about the potential
of the ‘digital era’, by focusing on the nature and impli-
cations of mergers between the roles and experiences
of ‘patients’, ‘participants’ and health ‘consumers’.
These mergers are, potentially, both hopeful and
unnerving, but they also carry implications beyond
this political and ethical duality.
Biomedicine and big data
The emergence of digital tools of data collection, col-
lation and analysis has altered the nature and focus of
biomedical research and healthcare. The preponder-
ance of so-called ‘big data’, i.e., large quantities of
varied, dynamic, easily collated, shared and distributed
data26, has not only impacted the conduct of biomed-
ical and health research, but also its effects have pene-
trated into the everyday lives and mundane interactions
of patients and citizens more generally, in ways that
have implications for how biomedical information is
derived and constructed.24,27 More generally, digital
and quantified health has become a significant dimen-
sion of contemporary healthcare and medical practice
in many countries. For instance, digital health and
medical technologies are being applied not only in
biomedical and public health research but also in
combination with electronic medical records for the
diagnosis, management and treatment of illness and
disease.2 Ongoing work by one of the present authors
explores how this is intertwined with the emergence of
new fields such as ‘digital psychiatry’, which has
the potential to reshape therapeutic encounters by
combining (or dissipating) patient testimonies based
on subjective experience with data collected via digital
means.28 These include so-called eHealth and Health
2.0 technologies and remote access care, as well as var-
ious mobile and wearable or implanted devices and
biosensors. The use of these technologies in healthcare
is producing new bio-techno-social populations.5,8
This, in turn, generates new ethical challenges in rela-
tion to how digital and social media are being and
should be used in healthcare, as well as to find
out about, and participate in, ongoing biomedical
health-related research. We need to ask how social
media is enabling or changing the involvement of
patients as participants in relation to health and
medical information,13 and, importantly, what the
ramifications of this are for their care.
Data-driven technologies such as myriad mobile
technologies, applications and digital devices, cloud
computing, social media and internetworked sensors
of various kinds increasingly structure both public
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and private spheres of life including the workplace,
home and leisure activities in addition to healthcare.
By using these technologies, we both generate and
take advantage of data that are aggregated and ana-
lysed by next-generation data analytics.29 This includes
data from social media platforms, which enable the
creation and sharing of user-generated content.
By facilitating collection of this generally unsolicited,
unmoderated and unsupervised content that can
capture details of (qualitative as well as quantitative)
information about disease experience that was previ-
ously largely outside the purview of medical research,
social media are reconfiguring how biomedical knowl-
edge is organised and created.30 The production and
archiving of patient-generated content and (patient)
data such as self-reporting of symptoms and recovery
that is shared through social media platforms is
increasingly used for medical research in ways that dis-
rupt traditional research modes characterised by organ-
isational settings like hospitals and traditional data
collection procedures.30 Hence, ‘digitally engaged
patients’2 become participants in, and co-producers
of, biomedical knowledge.31 Combined with inter-
twined phenomena, such as increased networking of
previously separate data infrastructures, and the open
data movement that promotes open and free access to
various kinds of data, big data are producing new data
assemblages.26 These assemblages are changing how
individuals and collective divisions are conceptualised
and framed in general and in the context of biomedi-
cine and healthcare in particular.
Big data analytics are designed to extract patterns of
information that can be evaluated to construct mean-
ing from the data abundance, such as patterns and
differences in disease progression and treatment
response within and between patient groups.32
The consequent effect of stratifying populations
through algorithmically created groupings has enabled
new kinds of ‘social sorting’ that are introducing new
categories of patients and diseases, at the same time as
they can reinforce existing ideas and cultural assump-
tions about social difference.29 Predictive analytics
applied to aggregated datasets can produce increasing-
ly powerful evidence of patterns, which are being
employed to shed new light on illness and disease risk
at population subgroup level. For example, the aggre-
gation of biomedical and population health data with
data not conventionally considered ‘medical’ can be
applied to identify population level patterns of
medically relevant information. Data now considered
medically relevant in this context include lifestyle data
collected from mobile applications, but also inter
alia educational attainment, criminal, income and
data collected by government and other public author-
ities to derive sociodemographic data. New medical
populations and subgroups are consequently emerging
through big data analytics, based on various previously
unknown shared biomarkers and biosocial indicators.
The delineation of these subgroups does not occur in a
social vacuum: cultural assumptions such as those
derived from race, gender and socio-economic inequal-
ities, including presumptions and stereotypes based on
social class, may be embedded in the algorithms
through which subgroups emerge. Such assumptions
can become reinforced in new ways through big data,
such as using credit scores to predict and grade health
risks including risk of cardiovascular disease.33
These phenomena not only signal changing ideas
about what counts as medical (or at least medically rel-
evant) data, but also illustrate a broader ongoing shift in
biomedical knowledge production away from conven-
tional evidence-based medicine.26 While evidence-based
medicine has prioritised (time consuming and expensive)
hypothesis-driven clinical trials and experimental stud-
ies, data-driven approaches and methods are increasing-
ly used to search for associations and correlations within
and across datasets, in real time.34
With regards to digital curation, patients’ medical
information is increasingly collected and stored in elec-
tronic health records that together form large databases
at a (regional and even national) population level. In
Scotland, for example, the Scottish National Health
Service and affiliated organisations collect and store
population medical records that are analysed to inter-
pret health patterns. Even more recent developments
include the Scottish Health Research Register
(SHARE) project, which is working to construct a reg-
ister of the Scottish population that agrees to provide
access to their personal medical records for the purposes
of further research.35 These exist alongside many other
similar large-scale population health data endeavours,
such as the ‘All of Us’ research programme in the
USA to construct an easy-access databank of medical
and health data from one million Americans36 and
whole genome sequencing initiatives like the associated
100,000 Genomes Project in England.37 The emergence
of digital and big data databanks and research modes
positions increasing numbers of patients and citizens as
research participants, as we contribute our medical,
health and lifestyle data to expanding data archives
that are used for biomedical research, population
health studies and healthcare interventions. Current
and future healthcare is wrapped up in such data initia-
tives, further blurring the research participant/patient
boundary and implying novel responsibilities of such
participation.
While, on the one hand, the availability of big health
data and big data analysis tools are focusing biomedical
and health research attention towards population level
research, on the other hand, research that applies
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population level data is increasingly aimed at translating
such data into personalised or individualised treatment
solutions.38 This creates a sphere of interaction in which
health is simultaneously increasingly individualised yet
understood through the lens of populations. Digita and
technology-based research tools and methods, such as
genomics and other so-called ‘-omics’ fields, such as
proteomics aimed at the collective characterisation of
proteins, and systems-level modelling of biomedical
data are increasingly hoped by biomedical, industry
and governmental commentators to enable better tar-
geted and more personalised treatments.39 Resonant
with shifts documented following the rise of such geno-
mic technologies in public health, digitisation enables
the direction of ‘scientific, biomedical, and public
health attention both inward [. . .] and outward’.40
Datafication and the construction of community
Practices of self-‘datafication’, most notably what is
often termed self-tracking and the ‘quantified self’
movement, are increasingly promoted by companies
and media commentators, as well as engaged in by a
variety of publics. These forms of voluntary self-
monitoring or surveillance feature the recording and
quantification of various features of everyday lives.41
In turn, these act as the basis for constructing digital
communities of self-trackers, within which one’s own
data can be shared and (re)interpreted through the lens
of data generated by others.41,42 These practices, and
the technologies that enable them, enact new represen-
tations and conceptualisations of the self in relation to
others, producing detailed biometrics of the body,
behaviour, lifestyle and environment that deconstruct
and reconstruct bodies and subjectivities in quantita-
tive terms. This process is especially visible in the
domain of health and wellness, where one’s nutritional,
fitness and other lifestyle data can be monitored, then
compared to a quantified health ‘norm’ that is created
by the aggregation of large quantities of lifestyle data
from others, and ultimately used to construct
self-knowledge that can be applied by individuals to
modify their lifestyle practices and ‘take responsibility’
for (or responsibilise) their own health.41,43
Simultaneously, digital and social media have inno-
vated patient options for interacting, generating net-
works, forming identities and communities, and
mobilising in unprecedented ways – as well as accessing
cutting-edge information about biomedical science and
technology, healthcare law and practice. Specialised
platforms such as PatientsLikeMe – and general plat-
forms like Facebook, Twitter and YouTube – partici-
pate in the production of patient experiences.
In particular, they enable the creation and sharing of,
and access to, content produced by patients about their
experiences of disease, illness, treatment and recovery.
By aggregating individual experiences, these platforms
function as databases of experience2 which include
advice and recommendations about treatment options
and forms of care that patients and prospective patients
can use as a resource in health-related decision-making.
Digital patient communities and spaces enable patients
to re-frame and challenge information and messages
distributed by competing organisations and agendas,
including officially authorised stories, to produce
counter-hegemonic discourses of their own that func-
tion as alternative knowledges.44 The discourses and
frames that individual patients are faced with will, in
turn, be influenced by the social networks to which they
belong. Digital networks are not neutral spaces: exist-
ing connections, as well as links enabled and forged by
the structure of the social media platform itself, influ-
ence which information and messages users encounter
and which interpretations they elect to make.
This circulation of digital and social media-
facilitated information is also connected with the
broader shifts in biomedical knowledge production
around which kinds of information can count as ‘evi-
dence’, not only in relation to the harnessing and use of
digital and social media data in biomedical research,
but also with regards to increasing disillusionment
among some publics with conventional medicine and
medical research. This is particularly evident when it
comes to controversial experimental and alternative
forms of treatment and medical intervention that are
marketed directly to consumers online, such as so-
called ‘unproven’ DTC stem cell therapies that do not
conform to the standards of evidence-based medicine,
including clinical trials.45–47 Information distributed by
DTC clinics offering these therapies as well as user-
generated content on social media provide alternative
sources of information, in addition to (or instead of)
conventional medical sources. This is especially
pertinent when patients’ priorities do not align with
the priorities of the medical and healthcare professio-
nals who treat them. Exemplary is the ‘right to try’
movement, which is focused on patients’ access to
experimental therapies and drugs. The movement has
unfolded at the intersection of patients’ priorities and
need for treatments for diseases for which no evidence-
based treatments exist – including conventionally dis-
regarded emotional needs such as the value of hope44,48
– and the priorities and concerns of medical and
research professionals working within evidence-based
epistemic frames.49 Their priorities are focused on
effectiveness, including cost effectiveness, and safety
of medical care, even when compassionate use and
experimental intervention remain part of the
medical framework.
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In addition to community formation around specific
disease categories, new participatory health communities
are consolidating through the populations produced by
the use of big data technologies and analytics in biomed-
icine, facilitated by social media. These include groups of
individuals identified through screening technologies as
being ‘at risk’ of a disease, who can then revise their
identity conceptions in relation to the ‘at risk’ category.
They can also act on information about how to manage
health under the condition of being ‘at risk’, in ways that
shape experiences and identity formation in relation to
health and illness even in the absence of a disease diag-
nosis.50 Ongoing work by one of the authors with col-
leagues51 explores how social media are facilitating the
formation of collective identities and digital communities
through shared experiences of being ‘at risk’ of cancer
due to inherited genetic syndromes. For individuals ‘at
risk’, social media such as online blogging enable not
only the formation of social connections around their
specific type of cancer risk,52 but also around experiences
shared with those with other inherited syndromes. This,
in turn, facilitates the construction of networks around
the notion of risk (and new fora for interpreting and
negotiating this notoriously slippery concept).
Digitally mediated network formation around these
emergent medical classifications illustrates how digital
and big data biomedical research technologies and dig-
ital and social media platforms can co-create new
forms of experiencing and interpreting the meaning of
patienthood, as well as participation in medical care
and (self- or risk-) monitoring. These include experien-
ces of patienthood ‘in waiting’51 that come to be con-
stituted in relation to risk of disease. The centring of
‘risk’ in these ways highlights that contemporary expe-
riences of patienthood are shaped not only by the dig-
ital era, but also by (related) socio-political changes in
how ‘risk’ is conceptualised and managed. Beck53
among others has argued that we are increasingly
living in ‘risk societies’, where omnipresent and
myriad forms of ‘risk’ (from environmental to terror-
ism to health) dominate public and political discourses.
In ‘risk societies’, ignorance or indifference towards
these risks is discursively positioned as a threatening
failure to anticipate and mitigate them: ‘not knowing’
or preparing for them gives rise to disaster, while
knowing and predicting enables risk mitigation and
control.54 In the context of health, emphasis on the
management and control of risks is exemplified by
public health governance shifts towards ‘responsibilisa-
tion’ and individual accountability over health, as well
as by increasing interest and investment in ‘preventa-
tive’ healthcare and the use of predictive analytics in
biomedical research.55
Commercialising and consuming health
In addition to carrying research and community value,
patient generated digital data have increasing commer-
cial uses. Social media data can be collected and com-
modified by the platform developers for profit,
including the on-selling of the data to clients in the
commercial and private healthcare sector.31 Such eco-
nomic practices give rise to complex ethical issues
including around ownership and quality of research,
control of health data and data infrastructures, and
new power asymmetries around data access.56 The
new and emerging modes of information access, shar-
ing and production as well as the kinds of value created
inextricably intertwine with the forms of communica-
tion and interconnectivity enabled by the digital era.
Efforts to attach commercial value to and profit
from health data have encouraged the emergence of
new relations that are increasingly blurring the bound-
aries of medicine, healthcare and commerce.29
For example, communication and IT companies such
as Vodafone, Apple and IBM have been working to
connect payers, healthcare providers and product inno-
vators by creating digital ecosystems that capitalise on
the self-tracking and internet-of-things movements.
These companies can conduct analytics of their own
through these ecosystems, and repackage and on-sell
the data as a product. Similarly, global management
consulting companies such as KPMG are investing in
health analytics, and applying their expertise in data
analytics in relation to ‘therapeutic value optimisation’
such as assessing and demonstrating a drug’s value as
well as tracking health outcomes.29 The entry of these
new participants into healthcare systems is re-routing
traditional relations of information flow between
payers, service providers, physicians and patients, as
well as blurring the lines between the public and
private, and medical and non-medical domains.29
These digital ecosystems, cross-spatial interconnec-
tivity and forms of communication are connected with
the emergence of new global healthcare markets which
simultaneously position individuals not only as patients
and research participants, but also as (health) consum-
ers. DTC marketing, often online, of experimental
therapies such as stem cell treatments taps into and
capitalises on patients’ need for hope and demands
for treatment despite lack of evidence for the treat-
ments’ effectiveness and safety.45 This can also render
patients as paying participants in the construction of an
evidence base for the effectiveness of experimental
medical interventions in the absence of clinical trials.
DTC marketing of biomedical technologies also
builds on broader discourses around patient and con-
sumer empowerment, at the same time as pushing
towards individuals taking greater responsibility for
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their own health. Such marketing has co-occurred with
the drive towards personalised medicine that has been
catalysed by advances in genomics and reorientations of
healthcare systems internationally.57 For example, com-
panies offering DTC genetic testing for disease suscep-
tibility appeal to the importance of self-knowledge in
relation to one’s personal genetic profile and related dis-
ease risk factors, often without the direct involvement of
healthcare professionals in interpreting the testing
results.58 The marketing of these services mobilises
claims to provide consumers with a map of genetic
risk factors that can be used to modify lifestyle behav-
iours in ways that enable individuals to improve their
health.10,59 Notably, genetic testing companies such as
23andMe have actively fostered consumer communities
through various online fora, including social media
platforms like Twitter and Facebook.
The rhetoric of empowerment is, however, intertwined
with ‘responsibilisation’, as taking greater responsibility
for one’s own health can easily translate into increased
expectations or obligations to maintain and promote per-
sonal health, in ways that can transfer responsibility
away from publicly funded healthcare organisations,
the modification of environmental influences on health
and towards individuals. Simultaneously, consumers are
increasingly being positioned as ‘active’, not only in
terms of health seeking, but also in terms of having con-
trol over how their data are used in emerging regulatory
and cultural environments. In particular, the new
EU-wide General Data Protection Regulation aims to
reinforce data subjects’ rights to privacy and protection
of personal data in digitised environments in ways that
have particular implications for ‘special’ (i.e. sensitive)
categories of data, such as health data.60
Indeed, the use of consumers’ and citizens’ health
data for commercial as well as for public health pro-
motion purposes raises questions about data owner-
ship, use and access, as well as about possible data
breaches and the harms that may consequently result.
For example, data breaches in relation to eHealth mon-
itoring technologies and applications – including fitness
and nutrition tracking but also disease symptom,
sexual activity and mental health tracking, among
other sensitive information – could carry serious
adverse implications if the data could be traced back
to those from whom it was collected.27 The possibility
of sharing these kinds of data with healthcare providers
also raises questions about the extent to which such
data could be used in treatment decision-making to
ensure compliance with behavioural regimes that have
been medically recommended, such as levels of physical
activity or food consumption.27 These questions are
especially pertinent in relation to socially stigmatised
groups such as those defined as overweight or obese;
stigmatised illnesses such as many mental health
conditions and sexually transmitted diseases; and stig-
matised behaviours such as sexual activities that fall
outside social norms.
Additionally, commercialised practices such as DTC
medicine also have the capacity to shape and reconfig-
ure the process of identity formation. In relation to
DTC genetic testing, for example, ‘knowing’ one’s
genetic and genomic constitution can enable the rein-
terpretation of one’s biogenetic–biographical position-
ality. Companies offering genetic testing services,
which have carried names such as ‘Knome’ and
‘deCODEme’, make explicit claims to the centrality
of genomic data in relation to the constitution of the
self, and many of these companies offer services such as
ancestry tracing – including information pertaining to
socially significant designators like ethnicity – in addi-
tion to disease susceptibility testing.61 Genomic data in
general, and commercial DTC genetic testing in partic-
ular, have enabled the formation of new medical cate-
gories and forged communities and ‘biosocial’
networks built on shared experiences of making sense
of genomic susceptibility data, such as communities of
individuals ‘at risk’ or ‘patients in waiting’.62 At the
same time, technologies like amniocentesis enable
people to entwine their cultural notions of parenthood
and family with genetic knowledge in ways that are re-
fashioning the culture and politics of reproduction.63
These developments have complex implications for
how social categories, identities and relationships
including ethnicity and kinship are understood, and
how biographical narratives are constructed.61
Conclusion
So-called participatory modes of biomedicine and
healthcare in the context of the ‘digital era’ of social
and digital media – and the heterogeneous identity and
(bio)social network formations and possibilities for
agency that are enabled by, and enacted through, dig-
ital tools – are reconfiguring and blurring the roles and
experiences of patienthood, participation, and health
and medical consumerism.4,7,9,31 These roles and expe-
riences are layered concurrently, and in new ways, onto
those who access, share and (co-)produce content that
can easily become data in semi-public digital spaces.
Together with big data informatics, analytics, related
new biomedical research modes and the ‘datafication’
of life, participatory digital era health biotechnologies
shape the constitution of new, often cross-border com-
munities, social movements, epistemologies, knowledge
practices and health markets,44,50,51 while excluding
others from such activities.23,24
Big data biotechnologies are facilitating the collec-
tion, collation and analysis of unprecedented quantities
of heterogeneous data on a population scale, at the
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same time as the large databases that result from this
enable population subgroup stratification. This, in
turn, is motivating a seemingly incompatible yet con-
current shift towards ‘personalised’ medicine and health-
care.21 The ‘datafication’ of citizens’ and patients’
experiences, embodiments and information more gener-
ally are reconfiguring how the self can be and is con-
ceptualised, and how medical knowledge can be and is
produced by researchers and healthcare professionals as
well as by citizens and patients themselves.3,29,31 The
forms of communication and interconnectivity facilitat-
ed by digital and social media platforms simultaneously
turn individuals into digital subjects and shape the forms
of identity, community and knowledge that are pro-
duced and circulate there.44,61 New kinds of commercial
value in turn emerge from and through the data abun-
dance and digital networks that enable medical and
health data to be harnessed for profit, as well as com-
modified and marketed directly to consumers.31,45,46,58,59
These intertwined phenomena have arisen and are
taking shape through and in response to the ‘digital
era’, and they underscore the evolving and increasingly
tangled roles of patients, participants and health con-
sumers as both subjects and agents of science and
healthcare. Such entanglements are, however, shaped
by the overarching social, economic and political con-
texts in which they are embedded, as well as by pre-
existing social and cultural disparities and inequities.
This implies that the empowering as well as problem-
atic potentials of digital era developments are both
constrained and facilitated by concurrent socio-
political movements. They are also constrained by
modes of social and economic stratification including
classed, racialised and gendered divisions that pre-date
the digital era. Indeed, the ‘digital era’ itself has not
materialised in the same way across contexts, but is
unevenly inter- and intra-nationally distributed along
the lines of broader global geo-political and socio-
economic as well as public health disparities.23
This brings to the fore the importance of continuous
ethical, social and political scrutiny of the proliferation
of rights and responsibilities attached to individuals,
groups and organisations in relation to new and emerg-
ing digital biotechnologies and participatory biomedi-
cine. In particular, attention needs to be directed
towards the rights and responsibilities of, as well as
benefits and harms to, those living and working
beyond the university and healthcare sectors who nev-
ertheless shape the production of biomedical and
health-related knowledge in important (and sometimes
under-appreciated) ways. Normative work, including
by one of the authors of this paper,27 has already
begun for developing frameworks that appropriately
account for the roles of these actors.21,56,63,64
There is, then, a need to work with fresh conceptual
tools for understanding the digitally mediated entangle-
ments of patienthood, participation and health
consumption, as well as the effects and consequences
of these entanglements for healthcare practices,
biomedical and health research and innovation. These
tools need to be tuned to address the intersection of big
data, ‘datafication’, emerging participatory medical
and healthcare modes, and related research innovation,
digital globalisation and global disparities, and new
forms of interaction including social media community
and identity formation. New social, ethical and legal
frameworks and solutions will require engaging across
disciplines, contexts and sectors; sharing and debating
widely and inclusively.7 This work is required, not only
to understand how the digital era is changing the roles
and practices of patient–participant–consumer, and
the consequences of these changes for future health
challenges, but also to intervene in ways that support
patient autonomy and improvements in health and
well-being.
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